Expression and clinical significance of the Trop‑2 gene in advanced non‑small cell lung carcinoma
- Authors:
- Aigui Jiang
- Xiaoyan Gao
- Degeng Zhang
- Lixin Zhang
- Huiyu Lu
View Affiliations
Affiliations: Department of Respiratory Medicine, Taizhou People's Hospital Affiliated to Medical College of The Nantong University, Taizhou, Jiangsu 225300, P.R. China, Department of Oncology, Taizhou People's Hospital Affiliated to Medical College of The Nantong University, Taizhou, Jiangsu 225300, P.R. China, Institute of Clinical Medicine, Taizhou People's Hospital Affiliated to Medical College of The Nantong University, Taizhou, Jiangsu 225300, P.R. China
- Published online on: May 29, 2013 https://doi.org/10.3892/ol.2013.1368
-
Pages:
375-380
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Abstract
The Trop‑2 gene has been examined in various carcinomas and is reported to be significantly associated with prognosis. Little is known with regard to Trop‑2 gene expression in advanced non‑small cell lung carcinoma (NSCLC). The present study investigated the expression of Trop‑2 and its association with the prognosis of advanced NSCLC. The clinical records of 87 patients with advanced NSCLC, consisting of 37 cases of squamous cell carcinoma (SCC) and 50 cases of adenocarcinoma (AdC), together with 17 tumor‑adjacent normal tissues, were retrospectively evaluated. Trop‑2 expression was measured using an immunohistochemical method and its association with clinicopathological data and prognosis was also evaluated. The expression of Trop‑2 was significantly higher in the cancer tissues compared with the tumor‑adjacent normal tissues, and significantly higher in SCC compared with AdC (P=0.018). In SCC, the overexpression of Trop‑2 was only correlated with the histological grade of the tumor (P=0.035) and no correlation was observed with gender, age, lymph node metastasis, TNM stage or Eastern Cooperative Oncology Group (ECOG) performance status (PS). In AdC, the overexpression of Trop‑2 was correlated with the histological grade, lymph node metastasis and TNM stage (P=0.01, 0.024 and 0.015, respectively), while no correlation with gender, age or ECOG‑PS was observed. The survival frequency was significantly higher in the Trop‑2‑negative patients compared with the Trop‑2‑positive patients [17.25 months (95% CI, 14.922‑19.577) vs. 13.274 months (95% CI, 11.507‑15.041); P=0.008]. The survival time was significantly longer in the Trop‑2‑negative AdC patients [17.275 months (95% CI, 14.575‑19.975) vs. 11.469 months (95% CI, 11.507‑15.041); P=0.002], but not in the SCC patients [17.167 months (95% CI, 12.428‑21.906) vs. 14.647 months (95% CI, 12.062‑17.232); P=0.276]. The multivariate analysis revealed that Trop‑2 expression [hazard ratio (HR) 2.381; P=0.038], TNM stage (HR, 2.193; P=0.03) and ECOG‑PS (HR, 2.696; P=0.007) were independent predictors for the survival outcome of patients with AdC. These results suggest that Trop‑2 overexpression is closely correlated with an unfavorable prognosis in advanced NSCLC. Trop‑2 is an independent prognostic marker and a potential new therapeutic target in advanced AdC.
View References
|
1.
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar
|
|
2.
|
Jiang HF and Bo JJ: Trophoblastic cell
surface protein 2 and tumor. J Int Oncol. 39:96–98. 2012.(In
Chinese).
|
|
3.
|
Ohmachi T, Tanaka F, Mimori K, Inoue H,
Yanaga K and Mori M: Clinical significance of TROP2 expression in
colorectal cancer. Clin Cancer Res. 12:3057–3063. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Fong D, Spizzo G, Gostner JM, et al:
TROP2: a novel prognostic marker in squamous cell carcinoma of the
oral cavity. Mod Pathol. 21:186–191. 2008.PubMed/NCBI
|
|
5.
|
Fong D, Moser P, Krammel C, et al: High
expression of TROP2 correlates with poor prognosis in pancreatic
cancer. Br J Cancer. 99:1290–1295. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Wang J, Day R, Dong Y, Weintraub SJ and
Michel L: Identification of Trop-2 as an oncogene and an attractive
therapeutic target in colon cancers. Mol Cancer Ther. 7:280–285.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Kobayashi H, Minami Y, Anami Y, et al
IASLC International Staging Committee; Cancer Research and
Biostatistics; Observers to the Committee; Participating
Institutions: Expression of the GA733 gene family and its
relationship to prognosis in pulmonary adenocarcinoma. Virchows
Arch. 457:69–76. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Pak MG, Shin DH, Lee CH and Lee MK:
Significance of EpCAM and TROP2 expression in non-small cell lung
cancer. World J Surg Oncol. 10:532012. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Groome PA, Bolejack V, Crowley JJ, et al
IASLC International Staging Committee; Cancer Research and
Biostatistics; Observers to the Committee; Participating
Institutions: The IASLC Lung Cancer Staging Project: validation of
the proposals for revision of the T, N, and M descriptors and
consequent stage groupings in the forthcoming (seventh) edition of
the TNM classification of malignant tumors. J Thorac Oncol.
2:694–705. 2007. View Article : Google Scholar
|
|
10.
|
Calabrese G, Crescenzi C, Morizio E, Palka
G, Guerra E and Alberti S: Assignment of TACSTD1 (alias TROP1,
M4S1) to human chromosome 2p21 and refinement of mapping of TACSTD2
(alias TROP2, M1S1) to human chromosome 1p32 by in situ
hybridization. Cytogenet Cell Genet. 92:164–165. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Taylor JT, Zeng XB, Pottle JE, et al:
Calcium signaling and T-type calcium channels in cancer cell
cycling. World J Gastroenterol. 14:4984–4991. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Nelsen CJ, Kuriyama R, Hirsch B, et al:
Short term cyclin D1 overexpression induces centrosome
amplification, mitotic spindle abnormalities, and aneuploidy. J
Biol Chem. 280:768–776. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Cubas R, Zhang S, Li M, Chen C and Yao Q:
Trop2 expression contributes to tumor pathogenesis by activating
the ERK MAPK pathway. Mol Cancer. 9:2532010. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Zhang B, Yao YF and Zhou P: Two novel
mutations identified in two Chinese gelatinous drop-like corneal
dystrophy families. Mol Vis. 13:988–992. 2007.PubMed/NCBI
|
|
15.
|
Markoff A, Bogdanova N, Uhlig CE, Groppe
M, Horst J and Kennerknecht I: A novel TACSTD2 gene mutation in a
Turkish family with a gelatinous drop-like corneal dystrophy. Mol
Vis. 12:1473–1476. 2006.PubMed/NCBI
|
|
16.
|
Alavi A, Elahi E, Tehrani MH, et al: Four
mutations (three novel, one founder) in TACSTD2 among Iranian GDLD
patients. Invest Ophthalmol Vis Sci. 48:4490–4497. 2007. View Article : Google Scholar : PubMed/NCBI
|
